MediSix Therapeutics

About MediSix Therapeutics

MediSix Therapeutics Pte Ltd is an early-stage cell therapy company that is taking a novel approach to develop chimeric antigen receptor (“CAR”) T cells to target T cell lymphoma and leukemia. The company was founded by Dario Campana, M.D. PhD. with initial investment from Lightstone Singapore, L.P., a Singapore-focused fund founded in 2016 by Lightstone Ventures.
YEAR FOUNDED:
2016
LEADERSHIP:
Founder: Dario Campana, M.D. PhD.

2 articles with MediSix Therapeutics